Trials Sponsors Conditions Drugs Pricing

Conditions

Keywords

GlomerulonephritisNephritisNephropathyKidney DiseasesUrologic DiseasesUrogenital DiseasesAutoimmune DiseasesImmune System DiseasesProteinuriaGlomerulonephritis, IGA

Outcome Measures

Primary Outcomes (1)

To evaluate the effect of JADE101 on Urine Protein Creatinine Ratio (UPCR) in participants with IgA nephropathy
Change from baseline in UPCR
Week 52

Secondary Outcomes (1)

To evaluate the effect of JADE101 on Estimated Glomerular Filtration Rate (eGFR) in participants with IgA nephropathy
Week 52

Study Arms (3)

JADE101 Q8W

EXPERIMENTAL

Subcutaneous (SC) injection of JADE101 with Q8W maintenance dosing

Drug: JADE101

JADE101 Q12W

EXPERIMENTAL

Subcutaneous (SC) injection of JADE101 with Q12W maintenance dosing

Drug: JADE101

Placebo

PLACEBO COMPARATOR

Subcutaneous (SC) injection of placebo during the placebo-controlled treatment period

Drug: Placebo

Interventions

JADE101Drug

JADE101 is supplied as sterile solution to be administered by SC injection.

JADE101 Q12WJADE101 Q8W

PlaceboDrug

Placebo is supplied as sterile solution to be administered by SC injection.

Placebo

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Adult participants with biopsy-confirmed primary IgAN.
UPCR ≥0.75 g/g or 24-hour protein excretion ≥1 g/day, as measured from an adequately collected 24-hour urine sample.

Sponsors & Collaborators

Jade Biosciences, Inc.
Industrylead

MeSH Terms

Conditions

Glomerulonephritis, IGAGlomerulonephritisNephritisKidney DiseasesUrologic DiseasesUrogenital DiseasesAutoimmune DiseasesImmune System DiseasesProteinuria

Condition Hierarchy (Ancestors)

Female Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsMale Urogenital DiseasesUrination DisordersUrological ManifestationsSigns and Symptoms

Study Officials

Li Li, MD
Jade Biosciences
STUDY DIRECTOR

Central Study Contacts

JADE101 Study Contact

CONTACT

+1 781-201-4703 JADE101clinicaltrials@jadebiosciences.com

Study Design

Study Type: interventional
Phase: phase 3
Allocation: RANDOMIZED
Masking: QUADRUPLE
Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: INDUSTRY
Responsible Party: SPONSOR

Study Record Dates

First Submitted

October 22, 2026

First Posted

October 29, 2026

Study Start

December 2026

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Primary Completion

June 2029

A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (3)

JADE101 Q8W

JADE101 Q12W

Placebo

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (3)

JADE101 Q8W

JADE101 Q12W

Placebo

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record